CD79A and nasopharyngeal carcinoma: A previous case-control study by the same group using a smaller but different subset of plasma samples from the Sihui cohort (20 cases, 40 controls) did not show that gp42-IgG or -IgA levels correlated with NPC protection or neutralizing activity in B cell or epithelial cell lines (14).